Modulatory Effects of Neonatal Exposure to TCDD, or a Mixture of PCBs, p,p'-DDT, and p,p'-DDE, on Methylnitrosourea-Induced Mammary Tumor Development in the Rat

Daniel Desaulniers,1 Karen Leingartner,1 Jose Russo,2 Garth Perkins,3 Brock G Chittim,4 Michael C. Archer,5 Michael Wade,1 and Jack Yang4

1Environmental and Occupational Toxicology Division, Bureau of Chemical Hazards, Environmental Health Directorate, Healthy Environment and Consumer Safety Branch, Department of Health, Ottawa, Ontario, Canada; 2Breast Cancer Research Lab, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA; 3Department of Laboratory Medicine, Ottawa Civic Hospital, Ottawa, Ontario, Canada; 4Wellington Laboratories, Guelph, Ontario, Canada; and 5Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

The role of organochlorine (OC) exposure in the etiology of breast cancer remains controversial. Thus, our objective was to determine whether the most abundant and toxic OCs found in human milk could, when ingested during the neonatal period, modulate the development of mammary tumors in the rat. We prepared a mixture composed of p,p'-dichlorodiphenyldichloroethane (DDT), its major metabolite, p,p'-dichlorodiphenyldichloroethene (DDE), and 19 polychlorinated biphenyls (PCB) based on their concentrations found in the milk of Canadian women. Neonate rats at 1, 5, 10, 15, and 20 days of age were gavaged with this mixture, at 10, 100, and 1,000 times the amount that a human baby would consume. An additional group received 2.5 µg 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)/kg body weight (bw) by gavage at 18 days of age, instead of the mixture. On day 21, all treatment groups, except for a control group and a 1,000-mix group, received a single intraperitoneal injection of methylnitrosourea (MNU, 30 mg/kg bw), the initiator of the carcinogenic process. The average number of rats per treatment group was 33. Rats were sacrificed when their tumors reached 1 cm in size, or at 308 days of age. We prepared mammary tumors and mammary gland whole mounts for histologic analysis. There were no significant effects when only the malignant or only the benign tumors were considered. After all benign and malignant lesions were pooled, the number of mammary tumors differed among all MNU-treated groups (p = 0.02) with more lesions developing in the MNU-1,000: (median = 4.5; p = 0.05) and MNU-TCD group (median = 5.5; p = 0.07) compared to the MNU-0 rats (median = 2). Compared to the MNU-0 group, the percentage of rats that developed palpable tumors (benign plus malignant) was slightly higher (p = 0.06) in the MNU-TCD group, but not in the MNU-1,000 group. The percentage of palpable tumors that were malignant was higher (p = 0.02) in the MNU-100 group (15/16, 94%) than in the MNU-0 group (10/18, 56%). The highest dose of the mixture delayed (p = 0.03) the development of tumors, but this was not observed with the MNU-TCD treatment. These results suggest that neonatal exposure to high doses of organochlorines could favor the development of MNU-induced mammary lesions, but also delays the development of palpable tumors in the rat. Key words DDE, DDT, mammary tumor, methylnitrosourea, organochlorines, PCB, rat, TCDD. Environ Health Perspect 109:739–747 (2001). [Online 13 July 2001] http://ehpnet1.niehs.nih.gov/docs/2001/109p739-747/desaulniers/abstract.html

Breast cancer is the most prevalent form of cancer in North American women (1,2). The death rate from breast cancer is decreasing while the incidence is slightly increasing, but this increase is statistically significant only in black American women (2). The acknowledged risk factors for breast cancer are genetic predispositions (3–6) and reproductive factors (7,8). These risk factors account for only 30–50% of the cases (5.9–12); thus, environmental factors (exposure to manmade and natural chemicals, dietary habits, lifestyle) are hypothesized to account for the remaining cases.

The possibility that exposure to environmental contaminants, such as organochlorines, may be linked with breast cancer risk was raised by some (9,13), although others disagree (14–16). Organochlorines include a large number of agricultural and industrial chemicals and by-products of combustion and incineration. Polychlorinated biphenyls (PCBs), dioxins, and p,p'-dichlorodiphenyltrichloroethane (DDT) are lipophilic organochlorines, they accumulate in fat, and they are present at the µg to mg/kg levels in human tissues and milk (17–27), confirming direct exposure of the mammary tissues. Some epidemiologic investigations have found no association, or even a negative one, between human tissue levels of PCB congeners, DDT, and p,p'-dichlorodiphenyl-dichloroethene (DDE) and breast cancer (28–38); but in specific subpopulations (7,22,29,33,34,39–42) or by testing specific congeners (27,33,43,44), some did detect significant associations. The hypothesis of a link between organochlorine exposure and breast cancer is challenged by the study of accidentally exposed populations. People accidentally exposed to mixtures containing PCBs, polychlorinated dibenzo-dioxins and -furans in central Taiwan in 1979 and in western Japan in 1968 (45,46), and to dioxin in 1976 in Seveso, Italy (47), have not yet been reported to have an increased rate of breast cancer.

Organochlorine compounds have numerous effects in vivo and in vitro, which suggest that they could modulate the development of mammary tumors. These include antiestrogenic (16) or estrogenic effects (13,48,49) and alteration of thyroid (50–52) and immune functions (53). In vitro, these chemicals can decrease (54,55) or increase (13,56) the proliferation of breast cancer cells or immortalized breast epithelial cells, by acting directly on the estrogen receptor or indirectly via metabolic or crosstalk pathways (57,58), or by modulating apoptotic processes (59,60). Deregulation of apoptosis and interference with hormonal actions are key factors influencing mammary tumor development. Animal studies, because of different exposure protocols, demonstrate inconsistencies in linking organochlorine exposure with mammary tumor development. Long-term standard regulatory studies do not support an association between dietary exposure to DDE, DDT, PCBs, or 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Address correspondence to D. Desaulniers, Environmental Health Centre, Bldg # 8, Tunney’s Pasture, Postal Locator 0803D, Ottawa, Ontario, Canada, K1A 0L2. Telephone: (613) 957-1552 (office); (613) 957-8035 (lab). Fax: (613) 941-4768 or (613) 946-2600. E-mail: Daniel_Desaulniers@hc-sc.gc.ca

We are grateful to L. Casavant, A. McM ahon, G. Meriken, and C. Tashiro for technical assistance; to W.G. Foster and R. Vincent, who were Section Heads supporting this project; to H.J. Thompson, J. M Cginley (AMC Cancer Research Center, Denver, CO), and J.E. Korkola (University of Toronto) for sharing methodologies; to J. Nakai and C. Parfett for reviewing this manuscript. Funded by Health Canada and the Toxic Substance Research Initiative.
(TCDD) with endocrine-related cancers in adult animals; however, these studies have limitations (61). DDE can either support the growth of an estrogen-responsive tumor in ovariectomized rats (62) or prevent mammary tumor development in dimethylbenzanthracene (DMBA)-treated rats (63). 3,3',4,4'-tetrachlorobiphenyl (PCB #77) can either potentiate the carcinogenic effect of DMBA (64) or prevent further development of mammary tumors in the rat (65). Acute exposure to TCDD (66) or other arylhydrocarbon receptor (Ah-R) agonists (67) in postpubertal rats inhibited mammary tumor development; however, development of the tumors was promoted when TCDD was administered in utero (68).

Overall, little attention has been devoted to the effects of perinatal exposure to organochlorines. Excretion of accumulated contaminants through breast milk is a major source of exposure to organochlorines for nursing infants (69). The neonates and fetuses in utero are exposed and, in animal studies, accumulate tissue levels higher than those measured in the mothers (70,71). Some have hypothesized that changes in the endocrine environment during the fetal and neonatal periods could increase the probability of future occurrence of breast cancer (22,72–76). We observed that a high dose of a mixture of the most abundant human milk contaminants (19 PCB congeners, p,p-DDT, and p,p-DDE) stimulated the proliferation of breast cancer cells in vitro (56). Thus, our objective was to determine whether exposure to this mixture by gavage from neonatal day 1 to day 20, or whether a single exposure to TCDD at neonatal day 18 could modulate the development of methyl nitrosourea (MNU)-induced mammary tumors.

Our results suggest that neonatal exposure to this organochlorine mixture (19 PCB congeners, p,p-DDT, and p,p-DDE) or to a single dose of TCDD (2.5 µg/kg) before MNU treatment favors the development of mammary lesions, but the mixture at a high dose delays the development of palpable tumors in the rat.

Materials and Methods

Animal model. MNU is a DNA-methylating agent believed to induce mammary tumor development by creating O6-methylguanine in the DNA, which activates the proto-oncogene Ha-ras by a G→A transition (second nucleotide) of codon 12 (77–79). It has also been suggested that MNU treatment selects for pre-existing cells with Ha-ras oncomutations (80–82). We selected the MNU-treated rat model because, a) as in the human disease, MNU-tumors are mostly estrogen dependent; b) the carcinomas induced are aggressive and locally invasive; c) in contrast to DMBA, MNU has a short half-life (<30 min) and need not be metabolized to become active, allowing us to decrease the confounding effects of metabolic enzyme induction by the mixture and by DMBA itself; and d) MNU treatment permitted us to study the development of both malignant and benign tumors within a shorter time frame than studies that examined the development of spontaneous mammary tumors, which are mostly benign and take more than 27 weeks to develop (83). Finally, the MNU was injected in prepubertal female rats at 21 days of age, a protocol shown to induce tumors more rapidly than when MNU is injected at 50 days of age (84).

Mixture composition. DDT, DDE, and PCB congeners detected in more than 75% of breast milk samples from Canadian women were included in the mixture according to the median concentrations in milk fat (20,21). Non-ortho-chlorinated PCBs (#77, 126, and 169) were also added to the mix, according to the mean (median values were not available) concentrations in human milk fat (19). The doses were prepared to mimic multiples (10×, 100×, and 1,000×) of the typical daily intake of PCBs, DDT, and DDE (3). A Canadian Caucasian newborn drinking 120 mL breast milk/kg body weight (bw) per day (19). Using the human milk fat concentration of each organochlorine and the milk fat concentration of a newborn (3.7% milk fat (85)), we calculated the daily intake of each organochlorine. All the

| Family of xenobiotics | Selected congeners | Human milk fatb | 1,000× Target concentrationc (µg/mL) | Analyzed concentrationd (µg/mL) | 1,000× Amount gavaged per dosee (µg/kg bw) |
|-----------------------|-------------------|-----------------|--------------------------------------|---------------------------------|-------------------------------------------|
| PCBsb                 |                   |                 |                                      |                                 |                                           |
| Non-ortho             | 77                | 0.008           | 0.039                                | 0.24                            | 1.22                                      |
|                       | 126               | 0.080           | 0.34                                 | 0.32                            | 1.98                                      |
|                       | 185               | 0.133           | 0.15                                 | 0.75                            |                                           |
| Mono-ortho            | 28                | 0.014           | 34.28                                | 33.60                           | 174.05                                    |
|                       | 66                | 1.74            | 7.40                                 | 7.70                            | 91.69                                     |
|                       | 74                | 16.47           | 74.30                                | 74.88                           | 384.87                                    |
|                       | 118               | 8.65            | 70.40                                | 70.40                           | 364.67                                    |
|                       | 156               | 2.14            | 24.60                                | 24.60                           | 127.43                                    |
| Di-ortho              | 99                | 98.54           | 122.00                               | 122.00                          | 631.96                                    |
|                       | 128               | 4.17            | 1.60                                 | 1.60                            | 81.40                                     |
|                       | 138               | 115.68          | 124.00                               | 124.00                          | 642.32                                    |
|                       | 153               | 27              | 115.68                               | 141.00                          | 730.38                                    |
|                       | 170               | 9               | 38.56                                | 37.60                           | 194.77                                    |
|                       | 180               | 9               | 77.12                                | 81.80                           | 423.72                                    |
|                       | 183               | 9               | 12.85                                | 19.00                           | 98.42                                     |
|                       | 194               | 3               | 29.99                                | 34.40                           | 178.19                                    |
|                       | 201               | 3               | 17.14                                | 16.60                           | 85.99                                     |
|                       | 203               | 3               | 12.85                                | 13.60                           | 70.45                                     |
| DDT                   | p,p-DDE            | 233             | 1.000                                | 1063.00                         | 5506.34                                   |
|                       | p,p-DDT            | 35              | 149.1                                | 158.00                          | 818.44                                    |
| Total xenobiotics     | 444               | 1903.67         | 2064.51                              | 10694.14                        |                                           |

aIn addition to the non-ortho chlorinated PCBs (PCB #77, 126, and 169), only DDE, DDT, and the PCB congeners present in more than 75% of samples from Canadian women were included in the mixture (20,21). Numbering system according to Ballisch and Zell (68). bMean concentration of non-ortho PCBs (19) and median concentration of other PCB and DDT congeners (20,21). Concentrations at the 10× and 100× level were prepared from dilution of the 1,000× mixture. The target concentrations are the expected quantities of organochlorines dissolved in corn oil. cAnalyzed concentrations indicate the actual concentrations in the 1,000× dosing solution, measured in a blind test by Wellington Laboratories (Guelph, Ontario, Canada). Amounts given to the neonates when gavaged with 5.18 mL/kg of the 1,000× mixture at day 1 (a cumulative dose equal to 1,000 times human milk intake at day 0, 1, 2, 3, 4, day 5 (a cumulative dose for day 5, 6, 7, 8, 9), day 10 (a cumulative dose for day 10, 11, 12, 13, 14), day 15 (a cumulative dose for day 15, 16, 17, 18, 19), and day 20 of age (a cumulative dose for day 20, 21, 22, 23, 24). dPCB congeners are separated according to the position of the chlorine substitution. eThe analyzed concentration is 7.87 times higher than the target concentration. This is the only major deviation from the target concentrations.
chemicals included in the mixture were >99% pure (AccuStandard Inc., New Haven, CT, USA), and were dissolved in dimethyl sulfoxide (DMSO), sometimes following heating at 55°C and sonication for 2 hr, before being diluted in corn oil at 30°C. A blind analysis of the complete mixture was performed to confirm the concentrations of each congener (Wellington Laboratories, Guelph, Ontario, Canada). This analysis revealed a very close match between our target and the analyzed concentrations, except for PCB #77, which had a concentration almost 8 times higher than expected. Some of the discrepancies could be caused by impurities in higher chlorinated PCBs (e.g., PCB #118). The composition and the doses of the high dose mixture are indicated in Table 1.

Animal treatment. Animal treatment was conducted in accordance with the Canadian Council on Animal Care guidelines (86). We could manipulate only a limited number of rats per week, so three litters including only neonate female Sprague-Dawley rats (10–11 females/litter) were prepared every week by the supplier (Charles River, St-Constant, Quebec, Canada), until we accumulated over the weeks approximately 30 female neonates per treatment group. On the day of arrival to the lab, at neonatal day 1 (day 0 is the day of birth), pups from all litters were separated from their dams and regrouped under a heating lamp. They were individually weighed, identified, and exposed by gavage to their first treatment before being returned at random to a fostering dam. Neonates were divided into 7 separate treatment groups: corn oil (0), 1,000×, MNU-0, MNU-10×, MNU-100×, MNU-1,000×, and MNU-TCD D. At ages 1, 5, 10, 15, and 20 days, the neonates received the vehicle or appropriate mixture by gavage, each dose representing 5 days of ingestion (Figure 1). At 18 days of age, the MNU-TCD D group treated only with oil at the above time points, also received 2.5 µg TCD D/kg bw, dissolved in corn oil by gavage [a dose 4 times smaller than one previously shown to inhibit mammary tumor development in the day 50 DM BA-induced rat model (66)]. On day 21 of age, all treatment groups, except the 0 and the 1,000× group, received a single intraperitoneal (ip) injection of MNU (30 mg/kg bw, dissolved in 0.9% NaCl, acidified to pH 4.0 with acetic acid), according to previous recommendations (87). The 0 and 1,000× groups received the vehicle only. Rats were weighed before each treatment and then every 10 days. The time of vaginal opening (assessed daily starting at day 25) was recorded as an indicator of puberty. Twice a week, beginning 4 weeks after the MNU injection, rats were manipulated to detect palpable tumors (the date, the location, and size of the tumor were recorded). Seven and nine rats from the 0 and 1,000× groups, respectively, were sacrificed between 55 and 62 days of age, and the remaining rats from these groups were sacrificed at 242 days of age. MNU-treated rats were sacrificed when their palpable tumors reached 1 cm, or by 308 days of age if no palpable tumor was detected. Rats were sacrificed by exsanguination between 0900 and 1200 hr, under isoflurane anesthesia.

Analysis of the mammary gland structures. We recorded the locations and dimensions of all palpable tumors from the time of detection until necropsy. During necropsy, the position and size of the tumors were noted and the tumors were excised from the mammary tissue, weighed, and cut in half, with one-half fixed in 10% neutral buffered formalin (NBF) and the other half frozen in liquid nitrogen. Paraffin sections (5 µm) of the fixed mammary tumors were prepared and stained with hematoxylin and eosin for histologic classification.

We prepared whole mounts by fixing the skin pelts in 10% NBF for 24–48 hr, and then dissected all the mammary tissue. We placed the left thoracic glands in tissue cassettes for later histologic analysis, and de-fat ted the rest of the mammary tissue in acetone for 6 days and hydrated it with 100%, 95%, and 70% ethanol for 1 hr each and with water for 30 min. We stained the tissues by immersing them in Alum Carmine Stain (0.4%) containing 0.015% thymol for 2 days. The glands were dehydrated (30 min in water followed by 1 hr each in 70%, 95%, and 100% ethanol) and immersed in xylene for a minimum of 1 hr. We then sealed the stained mammary preparations in plastic pouches containing methyl salicylate.

We observed all abdominal-inguinal and the right cervical-thoracic mammary glands carefully under a microscope and then under a microscope at 4x magnification. We noted and identified the various mammary structures according to procedures described by Russo and Russo (88). Structures that could not be identified by analysis of the whole mounts were dissected and transferred to paraffin blocks before being classified by histology (Table 2). In each animal we counted individually the number of abnormal structures—including intraductal proliferations (IDPs), microtumors, adenomas, hyperplastic alveolar nodules, cysts, and other cystic structures (buds, clumps, nodules, ducts, lobules, milk-filled cysts).

Statistical analysis. We performed all analyses using JMP software (89). To analyze the time of vaginal opening and the body weight (only when specific days were considered), we tested homogeneity of variance by O’Brien and Brown-Forsythe tests, and log-transformed the data when required (body weight on day 40) before conducting analysis of variance (ANOVA) and nonparametric chi-square analyses to compare the percentage of rats developing tumors among dose groups (Table 3). We assessed differences in the cancer incidence curves by survival curve analysis, using the log-rank test, which places more weight on later delay to tumor, and the Wilcoxon test, which places more weight on early delay to tumor. Significant differences were detected when \( p < 0.05 \), whereas a \( p > 0.1 \) suggested a tendency.

Results

Treatment effects on body weight are shown in Figure 2. There were no significant effects of the 1,000× dose compared to the 0 dose on body weight throughout the study. The TCD D treatment decreased growth rate, even before the MNU injection, as indicated by the smaller body weights of these rats on days 20 and 21 (\( p = 0.0002 \)) compared to those of all other groups. These early effects of TCD D on body weight did not persist, so that by day 40 these rats were similar in weight to the other MNU-treated rats. The MNU-treated rats, regardless of the dose of the mixture, had smaller body weights (ANOVA on repeated measures, with contrast, \( p = 0.04 \)) than the 0 and the 1,000× groups throughout the study, and this effect was significant as early as day 30 (\( p = 0.0001 \)).

Environmental Health Perspectives • VOLUME 109 | NUMBER 7 | July 2001
shows that the MNU-1,000× group had the smallest body weights from approximately day 75 until the end of the study, but these were not significantly different from those of the other MNU-treated rats.

The age at the time of vaginal opening was similar in the 0, 1,000×, and the MNU-1,000× dose groups (Figure 3). Except for the MNU-1,000× group, vaginal opening was delayed in all the MNU-treated rats, but significantly (p = 0.02) only in the MNU-10× and the MNU-100× groups.

Histologic analysis of all palpable tumors and small mammary lesions dissected from the whole mount preparations revealed the existence of different types of benign and malignant mammary lesions in the rat (Table 2). The groups not treated with MNU (0 and 1,000×) showed very few mammary lesions compared to all the groups treated with MNU. The most abundant lesions were benign hyperplasia of mammary cells within terminal end buds, identified as iDPs, and hyperplasia of alveolar and lobular structures. After all benign and malignant lesions were pooled, the number of rats that developed a number of malignant lesions in the rat (Table 2). The groups not treated with MNU (0 and 1,000×) showed very few mammary lesions compared to all the groups treated with MNU. The most abundant lesions were benign hyperplasia of mammary cells within terminal end buds, identified as iDPs, and hyperplasia of alveolar and lobular structures. After all benign and malignant lesions were pooled, the number of rats that developed a number of lesions above the median value significantly differed among MNU-treated groups (Table 2, p = 0.02), with more lesions developing in the MNU-1,000× (median = 4.5; p = 0.05) and MNU-TETD (median = 5.5; p = 0.07) than in the MNU-0 rats (median = 2).

Each point on the mammary tumor incidence curves (Figure 4) represents the cumulative percentage of rats that developed palpable tumors (benign and malignant; not including the microscopic lesions analyzed from the whole mount preparations) over time relative to the MNU injection (time = 0). Although the incidence curve of the MNU-TETD group tended to differ (p = 0.06) from that of the MNU-1,000× group, none of the incidence curves differed significantly from that of the MNU-0 group.

However, if the data are censored at 150 days [approximately the last day in a similar experiment (66)], the delay in the development of tumors in the MNU-1,000× dose group becomes statistically significant (p = 0.03). In addition, Figure 4 demonstrates that at the end of the experiment the percentage of rats that developed palpable mammary tumors was slightly increased (p = 0.06) by the MNU-TETD (18/32 = 56% rats with palpable tumors), but not by the other treatments (MNU-1,000× 13/34, 38%; MNU-100× 11/31, 36%; MNU-10×/28, 36%) compared to controls (MNU-0 14/41, 34%).

Table 2. Total number, median, and range of mammary lesions* per group.

| Mammary lesion          | 0 (n = 30) | 1,000× (n = 33) | 0 (n = 41) | 10× (n = 28) | 100× (n = 31) | 1,000× (n = 34) | TETD (n = 32) | P-Valueb |
|-------------------------|------------|-----------------|------------|--------------|---------------|---------------|-------------|-----------|
| Benign + malignant      |            |                 |            |              |               |               |             |           |
| n                       | 1          | 3               | 238        | 206          | 487           | 268           | 524         | 0.02      |
| m                       | 0          | 0               | 2          | 2            | 1             | 4.5           | 5.5         |           |
| r                       | 1          | 2               | 51         | 69           | 170           | 44            | 116         |           |
| Benign                  |            |                 |            |              |               |               |             |           |
| Fibroadenoma            | n          | 1               | 0          | 17           | 17            | 6             | 14          | 13        |
| m                       | 0          | 0               | 0          | 0            | 0             | 0             | 0           | 0.24      |
| r                       | 1          | 0               | 3          | 2            | 1             | 3             | 2           |           |
| Papilloma               | n          | 0               | 0          | 7            | 3             | 14            | 1           | 50        |
| m                       | 0          | 0               | 0          | 0            | 0             | 0             | 0           |           |
| r                       | 0          | 1               | 3          | 11           | 1             | 20            |             |           |
| Adenoma                 | n          | 0               | 0          | 7            | 13            | 5             | 16          | 14        |
| m                       | 0          | 0               | 0          | 0            | 0             | 0             | 0           | 0.68      |
| r                       | 0          | 2               | 6          | 2            | 7             | 3             |             |           |
| iDP/hyperplasia*        | n          | 0               | 0          | 2            | 118           | 335           | 156         | 331       |
| m                       | 0          | 0               | 0          | 0            | 0             | 0             | 0           | 0.73      |
| r                       | 0          | 2               | 28         | 64           | 140           | 37            | 61          |           |
| Total                   | n          | 1               | 2          | 149          | 177           | 360           | 187         | 408       |
| m                       | 0          | 0               | 1          | 1.5          | 1             | 2             | 3.5         | 0.12      |
| r                       | 1          | 2               | 34         | 64           | 140           | 37            | 82          |           |
| Malignant               |            |                 |            |              |               |               |             |           |
| Carcinoma in situ       | n          | 0               | 1          | 73           | 12            | 109           | 67          | 85        |
| m                       | 0          | 0               | 0          | 0            | 0             | 0             | 0           |           |
| r                       | 1          | 1               | 50         | 4            | 54            | 43            | 41          | 0.55      |
| Adenocarcinoma          | n          | 0               | 0          | 16           | 17            | 18             | 14          | 31        |
| m                       | 0          | 0               | 0          | 0            | 0             | 0             | 0           |           |
| r                       | 0          | 4               | 4          | 4            | 2             | 12            |             |           |
| Total                   | n          | 0               | 1          | 89           | 29            | 127           | 81          | 116       |
| m                       | 0          | 0               | 0          | 1            | 0             | 0             | 0           |           |
| r                       | 0          | 1               | 51         | 5            | 54            | 43            | 53          | 0.65      |

Abbreviations: m, median (the median is preferred because it is not drastically affected by extreme values in non-normally distributed population as is the mean); n, number of lesions per treatment group; r, range of lesions per treatment group (largest value – smallest value).

*Palpable tumors plus those detected by a microscopic analysis of the whole mounts. bP-Value of the median test only among the MNU-treated rats. cPreneoplastic lesions that, although benign, may grow to produce carcinomas. dHyperplasia of alveolar and lobular structures.
importance was the induction of 12 renal tumors that were not related to organochlorine treatment.

**Discussion**

The results suggest that TCDD and the highest dose of the PCB-DDT-DDE mixture could modulate the development of MNU-induced mammary tumors in the rat. The MNU-TCD and the MNU-1,000× groups had similar effects in increasing the median number of mammary lesions (Table 2), but the MNU-1,000× group, in contrast to the MNU-TCD group, transiently delayed the development of palpable tumors.

**Transient inhibition in the development of palpable mammary tumors.** The transient inhibition in the development of palpable mammary tumors observed in the MNU-1,000× group but not in the MNU-TCD group (Figure 4) is a phenomenon similar to that observed by Holcomb and Safe (66), but is probably not solely attributable to the activation of the Ah-R. After 10 µg/kg bw TCDD was administered at day 50, a dose 4 times higher than ours, Holcomb and Safe (66) observed at the end of their relatively short experiment (140 days of age) that only 1/10 TCD-treated rats, compared to 5/10 controls, developed DMBA-induced palpable mammary tumor. Although they concluded that TCDD prevented mammary tumor development in the rat, perhaps they would have observed only a transient delay if they had performed a longer experiment. In our experiment, the MNU-TCD treatment involved the administration of 87.5 ng TCDD (or 2.5 µg/kg bw) at day 18, and this did not inhibit tumor development. Three times less TCDD-toxic equivalents (TEQ) (PCB #77, 0.0001; #126, 0.1; #169, 0.01; #118, 0.0001; #156, 0.0005; #170, 0.0001, #180, 0.00005 (92)). Therefore, although the dosing regimes differ, mechanisms other than those directly related to the Ah-R binding might be involved.

The development of tumors induced by MNU or DMBA treatments is predominantly estrogen dependent (93–95). However, the transient inhibition in the detection of palpable tumors in the MNU-1,000× group might not be linked to reduced ovarian estrogen output or to anti-estrogenic effects. Vaginal opening in the rat indicates puberty and estrogen rise during the first estrous cycle. The time to vaginal opening was not delayed in the MNU-1,000× group; in fact, it was accelerated compared to the MNU-10× and MNU-100× groups (Figure 3). Also, ovarian follicular development was not altered by the 1,000× treatment in 21- and 224-day-old rats (96), suggesting that ovarian estrogen output might not be altered. Holcomb and Safe (66) suggested that the antitumorigenic effects of TCDD are attributable to anti-estrogens. TCDD and AhR agonists (65,67) exert antiestrogenic activity not by binding the estrogen receptor, but indirectly by inducing phase I and phase II drug-metabolizing enzymes (reviewed in Schrenk (57)), by down-regulation of the estrogen receptor (ER) and via crosstalk between the AhR and ER signaling pathways (58,97). However, antiestrogenic effects of TCDD depend on dose, tissue, species, and age, and are not detectable in 21-day-old rats (98). At high dose the PCB-DDT-DDE

**Table 3. Number of rats with mammary lesionsa per group.**

| Mammary lesion | 0 (n = 30) | 1,000× (n = 33) | 0 (n = 41) | 10× (n = 28) | 100× (n = 31) | 1,000× (n = 34) | TCDD (n = 32) | p-Valueb |
|----------------|-----------|----------------|-----------|-------------|-------------|---------------|-------------|----------|
| Benign + malignant | n | 1 | 0 | 2 | 28 | 24 | 22 | 25 | 24 | 0.54 |
| % | 3.3 | 6.1 | 68.3 | 85.7 | 71.0 | 73.5 | 75.0 | |
| Benign | Fibroadenoma | n | 1 | 1 | 0 | 12 | 13 | 6 | 9 | 10 | 0.25 |
| % | 3.3 | 3.0 | 7.3 | 4.3 | 4.7 | 4.3 | 4.7 | |
| Papilloma | n | 0 | 0 | 0 | 3 | 4 | 1 | 3 | 1 | 5 | 0.33 |
| % | 0.0 | 0.0 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Adenoma | n | 0 | 0 | 0 | 5 | 4 | 1 | 4 | 1 | 6 | 0.70 |
| % | 0.0 | 0.0 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| iDP/hyperplasia | n | 0 | 0 | 0 | 12 | 14 | 12 | 14 | 14 | 15 | 0.73 |
| % | 0.0 | 0.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | |
| Total benign | n | 1 | 1 | 0 | 15 | 18 | 15 | 14 | 16 | 22 | 0.72 |
| % | 3.3 | 3.0 | 63.4 | 64.3 | 54.8 | 70.6 | 68.8 | |
| Malignant | Carcinoma in situ | n | 0 | 0 | 1 | 5 | 5 | 8 | 7 | 4 | 0.55 |
| % | 0.0 | 0.0 | 3.0 | 12.2 | 17.9 | 25.8 | 20.6 | |
| Adenocarcinoma | n | 0 | 0 | 0 | 11 | 12 | 10 | 12 | 12 | 13 | 0.64 |
| % | 0.0 | 0.0 | 26.8 | 42.9 | 32.3 | 35.3 | |
| Total malignant | n | 0 | 0 | 0 | 15 | 15 | 12 | 15 | 15 | 14 | 0.70 |
| % | 0.0 | 0.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | |
| Other mammary observations | Cysts | n | 11 | 13 | 1 | 29 | 31 | 19 | 22 | 17 | 0.65 |
| % | 36.7 | 39.4 | 7.0 | 70.7 | 64.3 | 57.5 | 64.4 | |
| Fibrosis | n | 3 | 0 | 0 | 24 | 21 | 18 | 19 | 18 | 18 | 0.51 |
| % | 3.3 | 0.0 | 0 | 58.5 | 75.0 | 58.1 | 55.9 | |
| Lactational changesc | n | 2 | 0 | 1 | 21 | 17 | 17 | 18 | 11 | 0.30 |
| % | 6.7 | 0 | 0 | 51.2 | 60.7 | 54.8 | 52.9 | |
| Total | n | 11 | 13 | 1 | 32 | 33 | 25 | 28 | 25 | 25 | 0.98 |
| % | 36.7 | 39.4 | 78.1 | 82.1 | 80.7 | 82.4 | 78.1 | |

Abbreviations: n, number of rats; %, percent of group.

aPapillary tumors plus those detected by a microscopic analysis of the whole mounts. bThe p-value corresponds only to analysis of organochlorine effects within the MNU-treated rats; the comparison of the seven groups was always highly significant (p < 0.006), even for the incidence of cysts (p = 0.03), which is also elevated in the 0 and 1,000× groups. cObservation of milk secretions at necropsy or from the histologic analysis.
mixture stimulated the proliferation of MCF7-E3 cells in vitro, but had no uterotrophic effects in vivo in immature female rats (56). Thus, effects of the mixture and TCDD on the development of the mammary lesions may not be related only to the estrogenic or antiestrogenic properties of the chemicals.

Body weight differences among groups of rats on the order of 15–20% are known to inhibit mammary tumorigenesis (99). The body weights of rats treated with MNU-1000× were less than 9% smaller than the control group and were not significantly different from the other MNU-treated rats (Figure 2). We observed no inhibition of tumor development in the MNU-TCDD group even though the body weight was 18% smaller than that of the control group on day 30 [this difference decreased with aging (Figure 2)]. Thus, body weight differences cannot explain the transient inhibition in the detection of palpable tumors.

Increased number of mammary lesions. In the absence of MNU, the mixture of PCBs, DDT, and DDE does not induce the development of abnormal mammary structures (Table 2 and 3). Similarly, over a longer experiment, Kociba et al. (100) observed no increase in mammary tumors in the rat after dietary administration of 0.1 μg TCDD/kg/day from 7 weeks of age up to 2 years. They even reported a decreased incidence of spontaneous mammary tumors, but at a toxic dose that decreased the fertility of the rat (101) and induced hepatocarcinomas (100). Thus, the mammary gland does not appear to be a prime target for these chemicals. However, the increased median number of mammary lesions induced by MNU-TCDD and MNU-1,000× (Table 2) and the increased percentage of rats that developed palpable mammary tumors in the MNU-TCDD group (Figure 4) suggest that these treatments favored the initiation and/or promotion phases of the carcinogenic process. Others found that the carcinogenic potential of chemical initiators (DMBA or MNU) is increased by the administration of TCDD in utero (68), or at relatively low doses of PCB #77 (64), compared to high PCB #77 (65); TCDD (66)) or repetitive doses (67) of Ah-R agonists, which reduced tumor development. Brown et al. (68) suggested that TCDD treatment in utero potentiates the carcinogenic effects of DMBA by increasing the number of terminal end buds (TEBs) at the time of the DMBA injection at 50 days of age; the TEBs are suggested to be the target sites for the carcinogenic effects of chemical initiators (102). We observed no effects of the mixture on the size of the mammary glands or the number of TEBs at 21 days of age, the time of MNU injection (96). In vitro, a malignant transformation bioassay demonstrated that without pretreatment with initiating agents, no malignant foci are observed after continuous TCDD/PCB treatments; but extremely low concentrations of TCDD or PCB #126 (10⁻¹³ M), after initiation, promote malignant transformation (103). Collectively these results and ours suggest the existence of multiple time- and dose-dependent mechanisms modulating the development of chemically induced mammary tumors.

Tumor location and phenotype. In our study, most of the palpable tumors were from the abdominal-inguinal glands. In other studies in which tumors were initiated with DMBA (68) or MNU (86,104) at day 50 of age, tumors were located mostly in the thoracic region. Asynchronous postnatal development of the cervical-thoracic versus abdominal-inguinal glands was suggested to explain the predominance of thoracic tumors (88). We are not aware of other articles reporting the location of mammary tumors induced with MNU at 21 days of age in long-term studies. Perhaps at this age, the number of target cells for MNU is larger in the abdominal-inguinal chains of mammary glands than in the thoracic-cervical ones.

The percentage of malignant tumors was significantly higher in the 100× treatment group than in the control group, suggesting that the phenotype of the tumors might be modified by the mixture treatment. Nesaretnam et al. (64) observed that DMBA-induced tumors from rats treated with PCB #77 were mostly of the invasive phenotype. This observation is further supported by the fact that extremely low concentrations of TCDD or PCB #126 (10⁻¹³ M) promoted malignant transformation (103). In our study, changes in tumor phenotype did not follow a dose relationship, so this observation must be confirmed by other studies.
Relevance to human disease. Given the absence of detectable effects at the lowest dose level, our study might suggest that in humans the neonatal level of exposure to the chemicals included in our mix does not modulate tumor development. Regardless of the changes in tumor phenotype in the MNU-10× dose group, the increase in the median number of lesions occurred at a dose representing 1,000 times the amount of PCBs (19 congeners), DDT, and DDE that a human baby would consume during the first 24 days of life. In fact, the safety margin could be larger than 1,000. The concentrations of organochlorines in milk samples are not normally distributed, and the mixture contained non-ortho chlorinated PCBs based on mean levels, not the median levels; consequently, the proportions of non-ortho-chlorinated PCBs in the mixture exceed the proportions expected in most human milk samples. In addition, the amount of these PCBs in the mixture was slightly increased by the presence of eight times more PCB #77 than what we expected (Table 1). This difference might not have biologic consequences given that the TCD D-TEF for PCB #77 is 0.0001 (92), and it modifies the total TCD D-TEF exposure dose for the complete mixture from 31.42 to 31.44 ng. Nevertheless, a lack of information on the effects of more complete mixtures and on the effects occurring in utero, and a lack of understanding of the relations between toxicologic and carcinogenic processes, prevent us from ruling out the possibility of a link between TCD D, PCB, DDT, and DDE exposure and the risk of developing some types of breast cancer. Twenty-seven percent of the risk of developing breast cancer in twins derives from heritable factors (5). Twins are likely to receive similar exposures during the perinatal period, so the risk associated with in utero and/or neonatal exposure to organochlorines is likely to be smaller than 27%. Finally, the body burden in the human population is declining (69), which should decrease the risk for the general population even further.

The modulation of chemically induced mammary tumor development by organochlorines is an expensive but important experimental model for studying the initiation and the promotional phases of carcinogenesis. Moreover, it is one of the rare animal models providing quantifiable late outcomes following in utero or neonatal exposure to low doses of contaminants. Given that in the absence of an initiator, organochlorines have no effects on mammary tumor development, more research is required using the MNU or DMB A model to understand their mechanisms of action and how they are modulated by environmental contaminants. Such studies should determine the usefulness of this model as an indicator of adverse effects in humans, and could be used to identify epidemiologic markers of breast cancer susceptibility, and thus improve epidemiologic investigations.

In summary, we have shown that exposure during the neonatal period to TCD D or a mixture of PCBs, DDT, and DDE, before MNU treatment at neonatal day 21 increased the median number of mammary lesions (palpable and microscopic, benign and malignant) developing in the adult rat. The percentage of rats that developed palpable tumors (benign plus malignant) was also higher in the MNU-TCD D group than in the control group. The highest dose of the mixture delayed the development of palpable tumors, but the MNU-TCD D treatment did not. Perhaps treatments with TCD D or the highest dose of the mixture sensitize the mammary tissue to the carcinogenic effects of MNU by altering the initiation/early promotion phase of the carcinogenic processes. Then, the MNU-1,000× group exerted a transient inhibition of promotional mechanisms up to approximately 150 days after the MNU injection, or selected tumorigenic tissues responsive only to the late promotional factors. We are now assessing the dose-response effects of neonatal exposure to Ah-R agonists in human milk on the development of mammary lesions. It will remain

Figure 4. Mammary tumor incidence curves. Each point represents the cumulative percentage of rats that developed palpable tumors (benign and malignant) relative to the time of MNU injection (time = 0). The incidence curve of MNU-MNU-TCDD group differs almost significantly (p = 0.06) from the MNU-1,000× group. None of the incidence curves significantly differed from the MNU-0 group. At the end of the experiment the percentage of rats that developed mammary tumors was slightly increased (p = 0.06) by the MNU-TCD D (18/32 = 56% rats with palpable tumors) but not by the other treatments (MNU-1,000× 13/34, 38%; MNU-10× 11/31, 36%; MNU-10× 10/28, 36%) compared to controls (MNU-0 14/41, 34%).

Table 4. Incidence (percent of animals) of nonmammary tumors and organ abnormalities from tissues dissected during necropsy.

| Nonmammary tumors/organ abnormalities | MNU-treated mixture | 0 (n = 30) | 1,000× (n = 33) | 0 (n = 41) | 10× (n = 28) | 100× (n = 31) | 1,000× (n = 34) | TCDD (n = 32) |
|--------------------------------------|---------------------|-----------|----------------|-----------|-------------|-------------|----------------|-----------|
| Fibroma                              | 0                    | 0         | 0              | 0         | 0           | 0           | 0              | 0         |
| Ameloblastoma                        | 0                    | 0         | 0              | 0         | 0           | 0           | 0              | 0         |
| Keratoacanthoma                      | 0                    | 0         | 0              | 0         | 0           | 0           | 0              | 3.1       |
| Fibrohistiocytic tumor               | 0                    | 0         | 0              | 0         | 0           | 0           | 0              | 3.1       |
| Epidermoid cyst                      | 0                    | 0         | 0              | 0         | 0           | 0           | 0              | 3.1       |
| Abscessed salivary gland             | 0                    | 0         | 0              | 0         | 0           | 0           | 0              | 3.1       |
| Kidney                               | 3.3                  | 3.3       | 7.3            | 10.7      | 3.2         | 3.2         | 3.2             | 6.3       |
| Ovary                                | 0                    | 0         | 0              | 0         | 0           | 0           | 0              | 3.1       |
| Uterus                               | 3.3                  | 3.3       | 4.9            | 3.6       | 0           | 0           | 2.9             | 0         |
| Adrenal                              | 0                    | 0         | 2.4            | 7.1       | 3.2         | 3.2         | 2.9             | 3.1       |
| Pituitary gland                      | 0                    | 0         | 4.9            | 3.2       | 3.2         | 3.2         | 3.2             | 3.1       |
| Spleen                               | 0                    | 0         | 3.1            | 3.2       | 3.2         | 3.2         | 3.2             | 3.1       |
| Fur loss                             | 0                    | 0         | 0              | 0         | 0           | 0           | 0              | 3.1       |

* Tooth-related. 1 Skin tumors. 2 One animal had three epidermoid cysts. 3 All abnormal kidneys (12 in total) were renal mesenchymal tumors, except for one (MNU-0) which was glomerulonephritis. In one animal (MNU-10×) both kidneys were abnormal. 4 All ovarian follicular cysts (abnormally large clear follicles), except one thecoma (MNU-TCD D), one hemorrhagic ovarian cyst (MNU-10×), and one atrophic ovary (MNU-10×). 5 Not histologically classified, uterine bleeding. 6 One enlarged uterus (not classified), one with an endometrial polyp. 7 Endometritis. 8 Focal cystic hyperplasia. 9 Adenals were abnormally enlarged, but not histologically classified except for one (MNU-1,000×) which was an hemorrhagic infarction (not specific to treatment). 10 One enlarged adrenal was next to a kidney with a renal mesenchymal tumor. 11 Abnormal pituitary glands were not histologically classified. A dark area was observed on three pituitaries (MNU-0, MNU-100×, and MNU-TCD D groups), a white spot on an MNU-0–treated, and an MNU-1,000×–treated pituitary gland had blood inside. 12 Enlarged, not classified. 13 Two small cysts on side of spleen, not classified.
to be determined whether differences in the development of mammary lesions between treatment groups resulted from immediate toxic effects at the time of MNU injection, from persistent toxic effects, or from long-term effects altering the physiology of aging.

REFERENCES AND NOTES

1. National Cancer Institute of Canada. Canadian Cancer Statistics. Toronto, Canada: National Cancer Institute of Canada, 1999.

2. Ries LAG, Wingo PA, Miller DS, Howe HL, Wein HK, Rosenberg HM, Vernon SW, Conin K, Edwards BK. The annual report to the nation on the status of cancer, 1993-1997, with a special section on colorectal cancer. Cancer 88:2398-2424 (2000).

3. Dunnion AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomark Prev 8:843-854 (1999).

4. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, et al. Toxic effects at the time of MNU injection, persistent toxic effects, and mechanisms of action. In: Endocrine Disruptors: Effects on Male and Female Reproductive Systems (Naz RK, ed). New York: CRC Press, 1999; 187–221.

5. Soto AM, Sonnenschein C, Chung KL, Fernandez MF, et al. Modulation of mammary cancer risk and serum organochlorines and other organochlorines and breast cancer risk. Cancer Epidemiol Biomark Prev 9:553–60 (2000).

6. Moysich KB, Shields PG, Freudenheim JL, Schisterman EF, et al. DDE and DDT in breast adipose tissue and risk of breast cancer. Cancer Epidemiol Biomark Prev 8:525–532 (1999).

7. Moysich KB, Ambrosone CB, Vena JE, Shields PG, Marshall JR, Graham RK, et al. Risk of breast cancer associated with 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure in newly diagnosed patients undergoing breast surgery. Environ Res 34:24–28 (1984).

8. Hunter DJ, Hankinson SE, Laden F, Colditz GA, Manson J, Willett WC, Speizer FE, Wolff MS. Plasma organochlorine levels and the risk of breast cancer. N Engl J Med 347:1253–1258 (1997).

9. Lopez-Carrillo L, Blair A, Lopez-Cervantes M, Dichlorophenyl dichloroethane serum levels and breast cancer risk: a case-control study from Mexico. Cancer Res 57:3728–3732 (1997).

10. van't Veer L, Lobbezoo IE, Martín-Moreno JM. DDT (dichlorophen) and postmenopausal breast cancer in an area at high risk for breast cancer. Int J Cancer 58:251–254 (1994).

11. Basford KL, Beuchelt A, Vozikis GS, et al. Interactions of organochlorines on the thyroid hormone system; mechanisms and possible consequences for animal and human health. Toxicol Ind Health 14:59–84 (1998).

12. Porterfield SP, Hendry LB. Impact of PCBs on thyroid hormone directed brain development. Toxicol Ind Health 14:227–280 (1999).

13. Committee on Hormonally Active Agents in the Environment. Immunologic effects. In: Hormonally Active Agents in the Environment. Washington, DC: National Academy Press, 1999; 189–235.

14. Howick D, Willett K, Wilson C, Safe S, Estrous does not inhibit 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated effects in MCF-7 and hep3b1c1 cells. J Biol Chem 272:3070–3072 (1997).

15. Wang WL, Porter W, Burghardt R, Safe SH. Mechanism of inhibition of MDA-MB-468 breast cancer cell growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Carcinogenesis 20:2–9 (1999).

16. Desaulniers D, Leingartner K, Perkins G, Archer MC, Yang J, Wade M, Yagminas A. Modulation of mammary tumor development by a mixture of organochlorines found in human breast milk. (Abstr). Breast Cancer Res Treat 50(3):331 (1999).

17. Schenk D. Impact of dose-type induction of drug-metabolizing enzymes on the metabolism of endo- and xenobiotics. Biochem Pharmacol 56:185–192 (1998).

18. Zacharewski T, Safe S. Antiestrogenic activity of TCDD and related compounds. In: Reproductive and Developmental Toxicology (Korach KS, ed). New York: Marcel Dekker, Inc., 1999; 421–448.
71. Sinjari T, Klasson-Wehler E, Oskarsson A, Darnerud PO.
70. Darnerud PO, Sinjari T, Jonsson C-J. Foetal uptake of
69. Craan AG, Haines DA. Twenty-five years of surveillance
68. Brown NM, Manzolillo PA, Zhang J-X, Wang J,
66. Holcomb M, Safe S. Inhibition of 7,12-dimethylbenz(a)anthracene to female rats. J Natl Cancer Inst 55:652–657 (1975).
63. Silinskas KC, Okey AB. Protection by 1,1,1-trichloro-2,2-
62. Robison AK, Sirbasku DA, Stancel GM. DDT supports the
64. Nesaretnam K, Hales E, Sohail M, Krausz T, Darbre P.
65. Ekbom A, Hsieh C-C, Lipworth L, Adami H-O, Trichopoulos
63. Lu S-j, Archer MC. Ha-ras oncogene activation in mammary glands of N-methyl-N-nitrosourea-treated rats genetically resistant to mammary adenocarcinogenesis. Proc Natl Acad Sci USA 89:1001–1005 (1992).
62. Shinai K, Uemura Y, Fukumoto M, Tsukamoto T, Pascual R, Nandi S, Tsubura A. Synergistic effect of MNU and DMBA on initiation of spontaneous mammary tumorigenesis in rats. Carcinogenesis 17:2519–2524 (1996).
61. Holcomb M, Safe S. Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Lett 82:43–47 (1994).
60. Ramamoorthy S, White E, Daling JS, Sun G, M Clouga A, Safe SH, 3,3',4,4'-tetrachlorobiphenyl exhibits antiestrogenic and antitumorigenic activity in the rodent uterus and mammary cells and in human breast cancer cells. Cancer Lett 98:121–125 (1999).
59. Lenard Jr PD, Sinjari T, onjsini C-J, Fostetal uptake of coplanar polychlorinated biphenyls (PCBs) in human breast milk. Arch Environ Contam Toxicol 35:702–710 (1998).
58. Thompson HJ, Adlakha H. Dose-responsive induction of mammary gland carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis 18:2407–2411 (1997).
57. Frank R, Raper J, Smout MS, Braun HE. Organochlorine residues in adipose tissues, blood and milk from Ontario residents, 1976–1985. Can J Public Health 79:150–158 (1988).
56. Canadian Council on Animal Care. Guide to the Care and Use of Experimental Animals. Ottawa, ON: Canadian Council on Animal Care, 1993.
55. Thompson HJ, McGinley JN, Rothhammer K, Singh M, Ekbom A, Hsieh C-C, Lipworth L, Adami H-O, Trichopoulos A. Anticancerous activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Appl Pharmacol 133:313–320 (1995).
54. Balllschmier K, Zell M. Analysis of polychlorinated biphenyls by capillary gas chromatography. Anal Chem 302:20–31 (1980).
53. Kociba RJ, Keyes DG, Beyer J, Carreon RM, Wade CE, Ditteren DA, Kalins RP, Frauson LE, Park CM, Barnard SD, et al. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl Pharmacol 46:279–303 (1978).
52. Murray FJ, Smith FA, Nitschke KD, Humston CG, Kociba RJ, Schwartz BA. Three-generation reproduction study of rats given 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the diet. Toxicol Appl Pharmacol 50:241–252 (1979).
51. Russo J, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104:938–967 (1996).
50. Wolfle D. Interactions between 2,3,7,8-TCDD and PCBs as tumor promoters: limitations of TEFs. Teratog Carcinog Mutagen 17:217–224 (1998).
49. Lu J, Jiang C, Mtrenga T, Cutter G, Thompson HJ. Pathogenetic characterization of 1-methyl-1-nitrosourea-induced mammary carcinomas in the rat. Carcinogenesis 19:223–227 (1998).
48. Lu J, Jiang C, Mtrenga T, Cutter G, Thompson HJ. Pathogenetic characterization of 1-methyl-1-nitrosourea-induced mammary carcinomas in the rat. Carcinogenesis 19:223–227 (1998).
46. Holcomb M, Safe S. Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumorigenesis by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Lett 82:43–47 (1994).
45. Mc Dougal A, Wilson C, Safe S. Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. Cancer Lett 120:55–63 (1997).
44. Brown NA, Houghill PA, Zhang J-X, Wang J, Lamantiaire CN. Prenatal TCDD and predisposition to mammary cancer in the rat. Carcinogenesis 16:263–269 (1995).
43. Craan AG, Haines DA. Twenty-five years of surveillance for contaminants in human breast milk. Arch Environ Contam Toxicol 35:702–710 (1998).
42. Darnerud PO, Sinjari T, onjsini C-J, Fostetal uptake of coplanar polychlorinated biphenyl (PCB) congeners in mice. Pharmacol Toxicol 78:187–192 (1996).
41. Sinjari T, Klaasen-Chen, Schrager K, Darnerud PO. Methyltransferase and neonatal uptake of coplanar polychlorinated biphenyl (PCB) congeners in mice. Pharmacol Toxicol 78:187–192 (1996).
40. Thompson HJ, McGinley JN, Rothhammer K, Singh M, Ekbom A, Hsieh C-C, Lipworth L, Adami H-O, Trichopoulos A. Anticancerous activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Appl Pharmacol 133:313–320 (1995).
39. Balllschmier K, Zell M. Analysis of polychlorinated biphenyls by capillary gas chromatography. Anal Chem 302:20–31 (1980).
38. Kociba RJ, Keyes DG, Beyer J, Carreon RM, Wade CE, Ditteren DA, Kalins RP, Frauson LE, Park CM, Barnard SD, et al. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl Pharmacol 46:279–303 (1978).
37. Murray FJ, Smith FA, Nitschke KD, Humston CG, Kociba RJ, Schwartz BA. Three-generation reproduction study of rats given 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the diet. Toxicol Appl Pharmacol 50:241–252 (1979).
36. Russo J, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104:938–967 (1996).
35. Wolfle D. Interactions between 2,3,7,8-TCDD and PCBs as tumor promoters: limitations of TEFs. Teratog Carcinog Mutagen 17:217–224 (1998).
34. Lu J, Jiang C, Mtrenga T, Cutter G, Thompson HJ. Pathogenetic characterization of 1-methyl-1-nitrosourea-induced mammary carcinomas in the rat. Carcinogenesis 19:223–227 (1998).